Screener
Bicara Therapeutics BCAX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Investing activities: | ||
| Proceeds from maturities and sales of marketable securities | 101,000 | — |
| Purchase of property and equipment | (60) | — |
| Net cash provided by investing activities | 100,940 | — |
| Financing activities: | ||
| Proceeds from issuance on common stock and accompanying pre-funded warrants, net of issuance costs | 161,763 | — |
| Proceeds from exercise of options | 1,582 | 460 |
| Net cash provided by financing activities | 163,345 | 460 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's investing cash flow?
- Bicara Therapeutics (BCAX) reported investing cash flow of $100.94M in Q1 2026.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Bicara Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude